Class information for:
Level 1: GLICLAZIDE//ARTIFICIAL CELL MICROENCAPSULATION//BIOTECHNOL DRUG DEV

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
22786 369 36.6 74%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
176 3       DIABETES CARE//ENDOCRINOLOGY & METABOLISM//TYPE 2 DIABETES 58057
1896 2             METFORMIN//ACARBOSE//REPAGLINIDE 5944
22786 1                   GLICLAZIDE//ARTIFICIAL CELL MICROENCAPSULATION//BIOTECHNOL DRUG DEV 369

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 GLICLAZIDE authKW 1129725 17% 21% 64
2 ARTIFICIAL CELL MICROENCAPSULATION authKW 993011 3% 100% 12
3 BIOTECHNOL DRUG DEV address 623498 5% 42% 18
4 PHARMBIOSCI PRECINCT address 331004 1% 100% 4
5 BIOTECHNOL DRUG DEV BIOSCI PRECINCT address 248253 1% 100% 3
6 BIOSCI PRECINCT address 223415 2% 30% 9
7 BEZAFIBRATE INFARCT PREVENT COORDINATING address 186188 1% 75% 3
8 CHAIM SHEBA MED NEUFELD CARDIAC address 165502 1% 100% 2
9 PHARMCURTIN HLTH INNOVAT address 165502 1% 100% 2
10 SULFONYLUREA authKW 147028 12% 4% 44

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Endocrinology & Metabolism 5050 45% 0% 166
2 Pharmacology & Pharmacy 441 22% 0% 81
3 Cardiac & Cardiovascular System 252 11% 0% 42
4 Medicine, General & Internal 101 9% 0% 34
5 Materials Science, Biomaterials 50 2% 0% 8
6 Medicine, Research & Experimental 36 5% 0% 18
7 Peripheral Vascular Diseases 21 3% 0% 11
8 Chemistry, Applied 11 2% 0% 9
9 Toxicology 11 2% 0% 9
10 Engineering, Biomedical 10 2% 0% 7

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BIOTECHNOL DRUG DEV 623498 5% 42% 18
2 PHARMBIOSCI PRECINCT 331004 1% 100% 4
3 BIOTECHNOL DRUG DEV BIOSCI PRECINCT 248253 1% 100% 3
4 BIOSCI PRECINCT 223415 2% 30% 9
5 BEZAFIBRATE INFARCT PREVENT COORDINATING 186188 1% 75% 3
6 CHAIM SHEBA MED NEUFELD CARDIAC 165502 1% 100% 2
7 PHARMCURTIN HLTH INNOVAT 165502 1% 100% 2
8 INTERNAL MED DIABETOL CLIN PHARMACOL 121685 1% 29% 5
9 ELMELETI EGESZSEGTUDOMANYI INTEZET 110333 1% 67% 2
10 STEM CELL CANC BIOL 101842 1% 31% 4

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF DIABETES AND ITS COMPLICATIONS 13260 5% 1% 17
2 DIABETES OBESITY & METABOLISM 12162 5% 1% 18
3 DIABETES RESEARCH AND CLINICAL PRACTICE 7552 6% 0% 22
4 METABOLISM-CLINICAL AND EXPERIMENTAL 7319 8% 0% 28
5 DIABETES-METABOLISM RESEARCH AND REVIEWS 5755 3% 1% 10
6 ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 4300 1% 1% 5
7 EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 2628 2% 0% 7
8 PHILIPPINE JOURNAL OF INTERNAL MEDICINE 2506 0% 3% 1
9 JOURNAL OF PHARMACEUTICAL INNOVATION 1603 1% 1% 2
10 DIABETOLOGIA 1192 3% 0% 11

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 GLICLAZIDE 1129725 17% 21% 64 Search GLICLAZIDE Search GLICLAZIDE
2 ARTIFICIAL CELL MICROENCAPSULATION 993011 3% 100% 12 Search ARTIFICIAL+CELL+MICROENCAPSULATION Search ARTIFICIAL+CELL+MICROENCAPSULATION
3 SULFONYLUREA 147028 12% 4% 44 Search SULFONYLUREA Search SULFONYLUREA
4 SULPHONYLUREAS 124738 4% 11% 14 Search SULPHONYLUREAS Search SULPHONYLUREAS
5 CAS 21187 98 4 110333 1% 67% 2 Search CAS+21187+98+4 Search CAS+21187+98+4
6 1 4 2 4 BROMOBENZENESULFONAMINOETHYLPHENYLSULFONYL 3 TRANS 4 METHYLCYCLOHEXYLUREA 82751 0% 100% 1 Search 1+4+2+4+BROMOBENZENESULFONAMINOETHYLPHENYLSULFONYL+3+TRANS+4+METHYLCYCLOHEXYLUREA Search 1+4+2+4+BROMOBENZENESULFONAMINOETHYLPHENYLSULFONYL+3+TRANS+4+METHYLCYCLOHEXYLUREA
7 2 2 AZINO DI 3 ETHYL BENZOTHIAZOLINE 6 SULPHONIC ACID ABTS 82751 0% 100% 1 Search 2+2+AZINO+DI+3+ETHYL+BENZOTHIAZOLINE+6+SULPHONIC+ACID+ABTS Search 2+2+AZINO+DI+3+ETHYL+BENZOTHIAZOLINE+6+SULPHONIC+ACID+ABTS
8 7 ALPHA DIHYDROXY 12 KETO 5 BETA CHOLANATE 82751 0% 100% 1 Search 7+ALPHA+DIHYDROXY+12+KETO+5+BETA+CHOLANATE Search 7+ALPHA+DIHYDROXY+12+KETO+5+BETA+CHOLANATE
9 8IPGF2 ALPHA 82751 0% 100% 1 Search 8IPGF2+ALPHA Search 8IPGF2+ALPHA
10 ACRIDINE ORANGE LEUKOCYTE FLUOROGRAPHY 82751 0% 100% 1 Search ACRIDINE+ORANGE+LEUKOCYTE+FLUOROGRAPHY Search ACRIDINE+ORANGE+LEUKOCYTE+FLUOROGRAPHY

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 SINGH, AK , SINGH, R , (2016) IS GLICLAZIDE A SULFONYLUREA WITH DIFFERENCE? A REVIEW IN 2016.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. VOL. 9. ISSUE 6. P. 839 -851 38 50% 0
2 SIMPSON, SH , LEE, J , CHOI, S , VANDERMEER, B , ABDELMONEIM, AS , FEATHERSTONE, TR , (2015) MORTALITY RISK AMONG SULFONYLUREAS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.LANCET DIABETES & ENDOCRINOLOGY. VOL. 3. ISSUE 1. P. 43 -51 31 47% 20
3 MOGENSEN, UM , ANDERSSON, C , FOSBOL, EL , SCHRAMM, TK , VAAG, A , SCHELLER, NM , TORP-PEDERSEN, C , GISLASON, G , KOBER, L , (2015) METFORMIN IN COMBINATION WITH VARIOUS INSULIN SECRETAGOGUES IN TYPE 2 DIABETES AND ASSOCIATED RISK OF CARDIOVASCULAR MORBIDITY AND MORTALITY-A RETROSPECTIVE NATIONWIDE STUDY.DIABETES RESEARCH AND CLINICAL PRACTICE. VOL. 107. ISSUE 1. P. 104 -112 22 61% 4
4 AVOGARO, A , (2012) TREATING DIABETES TODAY WITH GLICLAZIDE MR: A MATTER OF NUMBERS.DIABETES OBESITY & METABOLISM. VOL. 14. ISSUE . P. 14-19 22 49% 9
5 ABDELMONEIM, AS , EURICH, DT , LIGHT, PE , SENIOR, PA , SEUBERT, JM , MAKOWSKY, MJ , SIMPSON, SH , (2015) CARDIOVASCULAR SAFETY OF SULPHONYLUREAS: OVER 40 YEARS OF CONTINUOUS CONTROVERSY WITHOUT AN ANSWER.DIABETES OBESITY & METABOLISM. VOL. 17. ISSUE 6. P. 523 -532 26 34% 7
6 ABDELMONEIM, AS , EURICH, DT , GAMBLE, JM , JOHNSON, JA , SEUBERT, JM , QIU, W , SIMPSON, SH , (2014) RISK OF ACUTE CORONARY EVENTS ASSOCIATED WITH GLYBURIDE COMPARED WITH GLICLAZIDE USE IN PATIENTS WITH TYPE 2 DIABETES: A NESTED CASE-CONTROL STUDY.DIABETES OBESITY & METABOLISM. VOL. 16. ISSUE 1. P. 22-29 19 46% 11
7 BO, S , CASTIGLIONE, A , GHIGO, E , GENTILE, L , DURAZZO, M , CAVALLO-PERIN, P , CICCONE, G , (2013) MORTALITY OUTCOMES OF DIFFERENT SULPHONYLUREA DRUGS: THE RESULTS OF A 14-YEAR COHORT STUDY OF TYPE 2 DIABETIC PATIENTS.EUROPEAN JOURNAL OF ENDOCRINOLOGY. VOL. 169. ISSUE 1. P. 117-126 20 44% 9
8 PANTALONE, KM , KATTAN, MW , YU, C , WELLS, BJ , ARRIGAIN, S , NUTTER, B , JAIN, A , ATREJA, A , ZIMMERMAN, RS , (2012) THE RISK OF OVERALL MORTALITY IN PATIENTS WITH TYPE 2 DIABETES RECEIVING DIFFERENT COMBINATIONS OF SULFONYLUREAS AND METFORMIN: A RETROSPECTIVE ANALYSIS.DIABETIC MEDICINE. VOL. 29. ISSUE 8. P. 1029-1035 15 58% 10
9 MOORANIAN, A , NEGRULJ, R , AL-SALAMI, H , (2016) THE IMPACT OF ALLYLAMINE-BILE ACID COMBINATIONS ON CELL DELIVERY MICROCAPSULES IN DIABETES.JOURNAL OF MICROENCAPSULATION. VOL. 33. ISSUE 6. P. 569 -574 14 58% 0
10 HORSDAL, HT , JOHNSEN, SP , SONDERGAARD, F , JACOBSEN, J , THOMSEN, RW , SCHMITZ, O , SORENSEN, HT , RUNGBY, J , (2009) SULFONYLUREAS AND PROGNOSIS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH DIABETES: A POPULATION-BASED FOLLOW-UP STUDY.DIABETES-METABOLISM RESEARCH AND REVIEWS. VOL. 25. ISSUE 6. P. 515-522 16 44% 25

Classes with closest relation at Level 1


Rank Class id link
1 6705 GLIMEPIRIDE//JTT 608//SECONDARY FAILURE
2 16766 METFORMIN HYDROCHLORIDE//GLIMEPIRIDE//GLICLAZIDE
3 8850 METFORMIN//LACTIC ACIDOSIS//BIGUANIDES
4 1970 INSULIN GLARGINE//BIPHASIC INSULIN ASPART 30//INSULIN INITIATION
5 3093 PIOGLITAZONE//THIAZOLIDINEDIONES//ROSIGLITAZONE
6 16225 REPAGLINIDE//NATEGLINIDE//MITIGLINIDE
7 761 ATP SENSITIVE K CHANNEL//K ATP CHANNEL//ATP SENSITIVE POTASSIUM CHANNEL
8 25009 ANTIDIABETIC PHARMACOTHERAPY//A HEFT//ACORN CSD
9 580 DPP 4 INHIBITOR//EXENATIDE//LIRAGLUTIDE
10 10600 INTENS CARDIAC CORONARY UNIT//ADMISSION GLUCOSE//ADMISSION GLYCEMIA

Go to start page